These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 8758211)

  • 41. Cyclin A expression in superficial spreading malignant melanomas correlates with clinical outcome.
    Flørenes VA; Maelandsmo GM; Faye R; Nesland JM; Holm R
    J Pathol; 2001 Dec; 195(5):530-6. PubMed ID: 11745687
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
    Chwirot BW; Kuźbicki Ł
    Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
    Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
    Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [HMB 45 positive balloon cells in combined nevi].
    Laaff H; Kühnl-Petzoldt C
    Hautarzt; 1992 Sep; 43(9):566-8. PubMed ID: 1399602
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of dicarbonyl/L-xylulose reductase (DCXR) in human skin and melanocytic lesions: morphological studies supporting cell adhesion function of DCXR.
    Cho-Vega JH; Vega F; Schwartz MR; Prieto VG
    J Cutan Pathol; 2007 Jul; 34(7):535-42. PubMed ID: 17576332
    [TBL] [Abstract][Full Text] [Related]  

  • 46. VEGF and VEGFR-2 immunohistochemistry in human melanocytic naevi and cutaneous melanomas.
    Pisacane AM; Risio M
    Melanoma Res; 2005 Feb; 15(1):39-43. PubMed ID: 15714119
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conjunctival melanocytic lesions. Natural history.
    Henkind P; Benjamin JV
    Trans Ophthalmol Soc U K (1962); 1977 Sep; 97(3):373-7. PubMed ID: 273993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The approach to the patient with a difficult melanocytic lesion.
    Elder DE; Xu X
    Pathology; 2004 Oct; 36(5):428-34. PubMed ID: 15370112
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
    Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
    Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential expression of N-cadherin distinguishes a subset of metastasizing desmoplastic melanomas.
    Attis MG; Burchette JL; Selim MA; Pham T; Soler AP
    Hum Pathol; 2006 Jul; 37(7):899-905. PubMed ID: 16784991
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of estrogen receptor beta in normal skin, melanocytic nevi and malignant melanomas.
    Ohata C; Tadokoro T; Itami S
    J Dermatol; 2008 Apr; 35(4):215-21. PubMed ID: 18419678
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
    Kuźbicki L; Gajo B; Chwirot BW
    Melanoma Res; 2006 Jun; 16(3):235-43. PubMed ID: 16718270
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nuclear pseudoinclusions in melanocytic naevi and melanomas.
    Rose DS
    J Clin Pathol; 1995 Jul; 48(7):676-7. PubMed ID: 7560180
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas.
    Glaessl A; Bosserhoff AK; Buettner R; Hohenleutner U; Landthaler M; Stolz W
    Arch Dermatol Res; 1999; 291(2-3):81-7. PubMed ID: 10195394
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Shifts in cadherin profiles between human normal melanocytes and melanomas.
    Hsu MY; Wheelock MJ; Johnson KR; Herlyn M
    J Investig Dermatol Symp Proc; 1996 Apr; 1(2):188-94. PubMed ID: 9627715
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Measuring S100 protein and neurone specific enolase in melanocytic tumours using video image analysis.
    Williams RA; Rode J; Dhillon AP; Jarvis LR; Skinner JM; Jamal O
    J Clin Pathol; 1986 Oct; 39(10):1096-8. PubMed ID: 2431005
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunoreactivity of alpha-melanocyte-stimulating hormone, adrenocorticotrophic hormone and beta-endorphin in cutaneous malignant melanoma and benign melanocytic naevi.
    Nagahama M; Funasaka Y; Fernandez-Frez ML; Ohashi A; Chakraborty AK; Ueda M; Ichihashi M
    Br J Dermatol; 1998 Jun; 138(6):981-5. PubMed ID: 9747358
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The carcinoembryonic antigen (CEA) family (CD66) expressed in melanocytic naevi is not expressed in blue naevuscell naevi in dendritic type.
    Egawa K; Honda Y; Kuroki M; Ono T
    J Cutan Pathol; 2000 Aug; 27(7):351-8. PubMed ID: 10917162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.